IL-6 levels analyzed in the blood sample collected at the first episode at admission and before reperfusion therapies in patients with and without stroke recurrence were similar (9.9 ± 10.4 pg/mL vs. 9.1 ± 7.0 pg/mL, p = 0.439), but different for TNFα (14.7 ± 5.6 pg/mL vs. 15.9 ± 5.7 pg/mL, p = 0.031) and sTWEAK (5,970.8 ± 4,330.4 pg/mL vs. 8,660.7 ± 5,119.0 pg/mL, p < 0.0001). Here, IL6 is linked to stroke disorder.